2025
Partial mitochondrial involvement in the antiproliferative and immunostimulatory effects of PT-112
Soler-Agesta R, Beltrán-Visiedo M, Sato A, Yamazaki T, Guilbaud E, Yim C, Congenie M, Ames T, Anel A, Galluzzi L. Partial mitochondrial involvement in the antiproliferative and immunostimulatory effects of PT-112. OncoImmunology 2025, 14: 2507245. PMID: 40386940, PMCID: PMC12091903, DOI: 10.1080/2162402x.2025.2507245.Peer-Reviewed Original ResearchConceptsImmunogenic cell deathTS/A cellsPD-L1Immune checkpoint inhibitorsExposure of calreticulinLigand PD-L1Type I IFN secretionSecrete type I IFNsRelease of HMGB1MHC class IMHC class I moleculesClass I moleculesType I IFNImmunostimulatory signalsCheckpoint inhibitorsCell surfaceTreatment discontinuationClinical responsePreclinical modelsMalignant cellsSolid tumorsTumor typesColorectal carcinomaGenetic alterationsHMGB1 release
2024
Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome
Khandakar B, Lacy J, Gibson J. Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome. Clinical Genetics 2024, 107: 469-474. PMID: 39660603, DOI: 10.1111/cge.14670.Peer-Reviewed Original ResearchLynch syndromeColorectal carcinomaResponse to immune checkpoint inhibitorsImpact of molecular classificationImmune checkpoint inhibitorsColorectal carcinoma developmentMismatch repairMicrosatellite instabilityResponse to treatmentPMS2 variantsCheckpoint inhibitorsPembrolizumab treatmentPathological responsePatient AGermline variantsColorectal adenocarcinomaMismatch repair proteinsMolecular classificationLS patientsThe combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers
Lee J, Park H, Jin H, Jin L, Yoo S, Cho N, Bae J, Kim J, Kang G. The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers. Journal Of Pathology And Translational Medicine 2024, 59: 50-59. PMID: 39440351, PMCID: PMC11736276, DOI: 10.4132/jptm.2024.09.26.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCaudal-type homeobox 2CD8 tumor-infiltrating lymphocytesTumor-infiltrating lymphocyte densitySurvival of patientsColorectal carcinomaStromal areaClinical outcomesHigh density of tumor-infiltrating lymphocytesDensity of tumor-infiltrating lymphocytesAdjuvant chemotherapy-treated patientsStage III colorectal carcinomaStage III colorectal cancerFOLFOX-treated patientsCancer-specific survivalChemotherapy-treated patientsIII colorectal carcinomaIII colorectal cancerTIL densityPrognostic factorsPrognostic parametersLymphocyte densityPrognostic markerCDX2 expressionColorectal cancerOutcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancerRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically Effective DoseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failure
2023
Colorectal Carcinoma With Sarcomatoid Components
Golconda U, McHugh K, Allende D, Collins K, Henn P, Lacambra M, Bejarano P, Groisman G, Loughrey M, Monappa V, Zhang X, Hornick J, Gonzalez R. Colorectal Carcinoma With Sarcomatoid Components. The American Journal Of Surgical Pathology 2023, 48: 465-474. PMID: 38155543, DOI: 10.1097/pas.0000000000002172.Peer-Reviewed Original ResearchConceptsSarcomatoid componentColorectal carcinomaUndifferentiated carcinomaTumor-infiltrating lymphocytesNodal metastasisAbdominal painDistant metastasisRare subtypeSMARCA4 lossTumor buddingHeterologous elementsRepair protein expressionRectosigmoid regionSpindle cellsGastrointestinal bleedingKeratin-positivePoor prognosisFollow-upCarcinomaMismatch repair protein expressionMolecular testingAdvanced stageTumorLoss of mismatch repair protein expressionProtein expressionRare tumors: Opportunities and challenges from the Children’s Oncology Group perspective
Schultz K, Chintagumpala M, Piao J, Chen K, Shah R, Gartrell R, Christison-Lagay E, Pashnakar F, Berry J, O'Neill A, Vasta L, Flynn A, Mitchell S, Seynnaeve B, Rosenblum J, Potter S, Kamihara J, Rodriguez-Galindo C, Hawkins D, Laetsch T. Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective. 2023, 2: 100024. PMID: 37829670, PMCID: PMC10566015, DOI: 10.1016/j.ejcped.2023.100024.Peer-Reviewed Original ResearchTumor CommitteeStromal tumorsDesmoplastic small round cell tumorSmall round cell tumorGastrointestinal stromal tumorsNonmelanoma skin cancerRound cell tumorGonadal stromal tumorPleuropulmonary blastomaRare tumorAdrenocortical carcinomaNeuroendocrine tumorsCell tumorsRare cancersChildhood cancerColorectal carcinomaPancreatic tumorsNasopharyngeal carcinomaThyroid carcinomaHigh-quality researchCarcinomaSkin cancerTumorsYoung adultsCancerChildren's Oncology Group's 2023 blueprint for research: Rare tumors
Schultz K, Chintagumpala M, Piao J, Chen K, Gartrell R, Christison‐Lagay E, Berry J, Shah R, Laetsch T, Committee T. Children's Oncology Group's 2023 blueprint for research: Rare tumors. Pediatric Blood & Cancer 2023, 70: e30574. PMID: 37458616, PMCID: PMC10529839, DOI: 10.1002/pbc.30574.Peer-Reviewed Original Research
2021
Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization
Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021, 35: 3261-3270. PMID: 34697157, PMCID: PMC8627740, DOI: 10.21873/invivo.12621.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationTrans-arterial chemoembolizationNeuroendocrine tumorsColorectal carcinomaIntrahepatic cholangiocarcinomaLipiodol depositionWashout rateContrast-enhanced magnetic resonanceMetastatic liver tumorsColorectal carcinoma tumorsLiver metastasesHepatic metastasesTumor responseTarget lesionsRetrospective analysisLiver tumorsSmall tumorsChemoembolizationCarcinoma tumorsTumorsExponential washoutCarcinomaTomography imagingWashoutCholangiocarcinomaClinicopathological significance of neutrophil-rich colorectal carcinoma
Rottmann BG, Patel N, Ahmed M, Deng Y, Ciarleglio M, Vyas M, Jain D, Zhang X. Clinicopathological significance of neutrophil-rich colorectal carcinoma. Journal Of Clinical Pathology 2021, 76: 34-39. PMID: 34312298, PMCID: PMC10910606, DOI: 10.1136/jclinpath-2021-207702.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalColorectal carcinomaHistological gradeTumor locationRight-sided tumor locationTumor cellsDNA mismatch repair (MMR) statusIndependent risk factorKaplan-Meier analysisHigh histological gradeAdvanced TNM stageMismatch repair statusPrognostic significanceCRC casesClinicopathological significanceTNM stageMetastasis stagePatient prognosisRisk factorsClinicopathological parametersMultivariate analysisRepair statusPatientsCarcinomaHigh rateMacrophage-derived netrin-1 drives adrenergic nerve–associated lung fibrosis
Gao R, Peng X, Perry C, Sun H, Ntokou A, Ryu C, Gomez JL, Reeves BC, Walia A, Kaminski N, Neumark N, Ishikawa G, Black KE, Hariri LP, Moore MW, Gulati M, Homer RJ, Greif DM, Eltzschig HK, Herzog EL. Macrophage-derived netrin-1 drives adrenergic nerve–associated lung fibrosis. Journal Of Clinical Investigation 2021, 131: e136542. PMID: 33393489, PMCID: PMC7773383, DOI: 10.1172/jci136542.Peer-Reviewed Original ResearchConceptsNetrin-1Lung fibrosisCell-specific knockout miceΑ1-adrenoreceptor blockadeIPF lung tissueNeuronal guidance proteinsNetrin-1 expressionExtracellular matrix accumulationAdrenergic processesAdrenoreceptor antagonismAdrenoreceptor blockadeFibrotic histologyInflammatory scarringIPF cohortAdrenergic nervesΑ1-blockersImproved survivalColorectal carcinomaLung tissueKnockout miceCollagen accumulationFibrosisMatrix accumulationMacrophagesGuidance proteins
2019
Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade
Wang T, Lee L, Vyas M, Zhang L, Ganesh K, Firat C, Segal N, Desai A, Hechtman J, Ntiamoah P, Weiser M, Markowitz A, Vakiani E, Klimstra D, Stadler Z, Shia J. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Modern Pathology 2019, 32: 1551-1562. PMID: 31175329, PMCID: PMC6849386, DOI: 10.1038/s41379-019-0289-6.Peer-Reviewed Original ResearchConceptsMicrosatellite instability-high tumorsTumor-infiltrating-lymphocytesColorectal carcinomaPathological characteristicsCheckpoint inhibitorsLymphocytic infiltrationResponse to immune checkpoint blockadeResponse to immune checkpoint inhibitorsMLH1 promoterImmune checkpoint blockadeImmune checkpoint inhibitorsSolid growth patternInter-tumor heterogeneityMicrosatellite instability-highRight-sided locationLynch syndrome-associatedCheckpoint blockadePD1/PD-L1Glucose Metabolic Reprogramming and Cell Proliferation Arrest in Colorectal Micropapillary Carcinoma
Vyas M, Patel N, Celli R, Wajapeyee N, Jain D, Zhang X. Glucose Metabolic Reprogramming and Cell Proliferation Arrest in Colorectal Micropapillary Carcinoma. Gastroenterology Research 2019, 12: 128-134. PMID: 31236153, PMCID: PMC6575135, DOI: 10.14740/gr1145.Peer-Reviewed Original ResearchColorectal micropapillary carcinomaGlucose transporter 1Micropapillary carcinomaGlucose metabolic reprogrammingColorectal carcinomaGlandular componentMetabolic reprogrammingGlycogen metabolismFrequent lymphovascular invasionCancer cell growthMPC therapyLymphovascular invasionTumor cell survivalAggressive variantPoor outcomeCell cycle arrestColon cancer cellsKi-67Glycogen metabolizing enzymesMetabolizing enzymesCarcinomaTransporter 1Cell proliferation arrestHCT116 colon cancer cellsReal-time PCR analysis
2018
Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation
Wu X, Snir O, Rottmann D, Wong S, Buza N, Hui P. Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Modern Pathology 2018, 32: 650-658. PMID: 30443012, DOI: 10.1038/s41379-018-0179-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorColorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsEndometrial NeoplasmsFemaleGenetic LociGenetic Predisposition to DiseaseHumansImmunohistochemistryMicrosatellite InstabilityMiddle AgedMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinPhenotypePolymerase Chain ReactionPredictive Value of TestsReproducibility of ResultsConceptsEndometrial cancerMLH1/PMS2Endometrial carcinomaMSH6 lossMicrosatellite shiftCancer cohortMismatch repair deficiency testingMicrosatellite instability-high colorectal cancerEndometrial cancer cohortLoss of PMS2Clear cell carcinomaColorectal cancer cohortHigh colorectal cancerLynch syndrome familiesMSH2/MSH6PMS2 lossCell carcinomaColorectal cancerDeficiency testingSolid malignanciesColorectal carcinomaCarcinomaCancerIsolated lossMSH-6Clinical, Histologic, and Immunophenotypic Features of Serrated Polyps in Patients With Inflammatory Bowel Disease
Yang C, Tarabishy Y, Dassopoulos T, Nalbantoglu I. Clinical, Histologic, and Immunophenotypic Features of Serrated Polyps in Patients With Inflammatory Bowel Disease. Gastroenterology Research 2018, 11: 355-360. PMID: 30344807, PMCID: PMC6188039, DOI: 10.14740/gr1064w.Peer-Reviewed Original ResearchInflammatory bowel diseaseSSA/PsHyperplastic polypsSerrated polypsBowel diseaseSporadic serrated polypsLow-grade dysplasiaSessile serrated adenomas/polypsSerrated adenomas/polypsImmunohistochemistry staining patternsTraditional serrated adenomasSite-matched controlsColorectal serrated polypsAdenomas/polypsSporadic colorectal carcinomasOlder patientsClinicopathologic featuresImmunophenotypical featuresImmunophenotypic featuresColorectal carcinomaStudy groupPatientsSerrated adenomasStaining patternPolypsCellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas
Liu S, Gӧnen M, Stadler Z, Weiser M, Hechtman J, Vakiani E, Wang T, Vyas M, Joneja U, Al-Bayati M, Segal N, Smith J, King S, Guercio S, Ntiamoah P, Markowitz A, Zhang L, Cercek A, Garcia-Aguilar J, Saltz L, Diaz L, Klimstra D, Shia J. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Modern Pathology 2018, 32: 110-121. PMID: 30166615, PMCID: PMC6309293, DOI: 10.1038/s41379-018-0114-7.Peer-Reviewed Original ResearchConceptsPD-L1 expressionMismatch repair-proficient tumorsImmune cell stainingMismatch repair-deficient tumorsPD-L1Tumor-infiltrating-lymphocytesColorectal carcinomaTumor cellsImmune cell PD-L1 expressionMismatch repair-deficient colorectal carcinomasTreatment of colorectal carcinomaMolecular sub-classificationLigand PD-L1Mismatch repair-deficient colorectal cancerHigher lymphocyte countMismatch repair-proficientCell stainingCellular localizationPD-1Mismatch repair deficiencyPredictive biomarkersLymphocyte countMolecular subtypesClinical efficacyTumor types
2017
Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival
Ptashkin R, Pagan C, Yaeger R, Middha S, Shia J, O'Rourke K, Berger M, Wang L, Cimera R, Wang J, Klimstra D, Saltz L, Ladanyi M, Zehir A, Hechtman J. Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research 2017, 15: 708-713. PMID: 28184012, PMCID: PMC5588907, DOI: 10.1158/1541-7786.mcr-16-0352.Peer-Reviewed Original ResearchConceptsMSK-IMPACTOverall survivalColorectal carcinomaLeft-sided colon cancerHigh-resolution microarraysAdvanced colorectal carcinomaColorectal carcinoma patientsWild-type KRASGenome copy numberNext-generation sequencingColorectal cancer patientsCancer Genome AtlasPrimary tumorCarcinoma patientsMutant TP53Clinical featuresCopy numberRAS/RAF mutationsColon cancerCancer patientsMRNA upregulationMultivariate analysisTranscript expressionPatientsMicrosatellite stability
2016
Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial–mesenchymal transition
Gonzalez RS, Huh WJ, Cates JM, Washington K, Beauchamp RD, Coffey RJ, Shi C. Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial–mesenchymal transition. Histopathology 2016, 70: 223-231. PMID: 27560620, PMCID: PMC5921077, DOI: 10.1111/his.13068.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionColorectal carcinomaDistant metastasisImmunohistochemical evidenceEvidence of EMTAdvanced T categoryConventional colorectal carcinomaCystic nodal metastasisStage IV diseaseAdvanced local diseaseLymph node metastasisMicrosatellite instability testingBRAF V600E mutationMedian survivalMucinous featuresOverall survivalNodal metastasisNode metastasisLocal diseaseMicropapillary featuresT categoryDirty necrosisCribriform patternKRAS mutationsProminent necrosisPatterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lee L, Cavalcanti M, Segal N, Hechtman J, Weiser M, Smith J, Garcia-Aguilar J, Sadot E, Ntiamoah P, Markowitz A, Shike M, Stadler Z, Vakiani E, Klimstra D, Shia J. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology 2016, 29: 1433-1442. PMID: 27443512, PMCID: PMC5083129, DOI: 10.1038/modpathol.2016.139.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1PD-1-positive tumor-infiltrating lymphocytesProgrammed death-ligand 1 expressionTumor-infiltrating lymphocytesProgrammed death-1Mismatch repair-deficient colorectal carcinomasRecurrence-free survivalAnti-PD-1 therapyPD-L1 expressionColorectal carcinomaMismatch repair-deficient tumorsPredictive markerPrognostic impact of tumor-infiltrating lymphocytesResponse to anti-PD-1 therapyHigh programmed death ligand-1Impact of tumor-infiltrating lymphocytesProgrammed death ligand 1 levelPD-1 levelsTumor PD-L1 expressionProgrammed death-1 expressionAssociated with better prognosisMismatch repair-proficient tumorsImmune checkpoint blockadePD-1 expressionPD-L1 immunohistochemistryRecurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma
Javier B, Yaeger R, Wang L, Sanchez-Vega F, Zehir A, Middha S, Sadowska J, Vakiani E, Shia J, Klimstra D, Ladanyi M, Iacobuzio-Donahue C, Hechtman J. Recurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. Oncotarget 2016, 7: 50875-50882. PMID: 27248473, PMCID: PMC5239443, DOI: 10.18632/oncotarget.9682.Peer-Reviewed Original ResearchConceptsSOX9 mutationsColorectal carcinomaWild typeAllele-specific copy numberNext generation sequencing dataGeneration sequencing dataProtein expressionAdvanced colorectal carcinomaColorectal carcinoma patientsWild type statusSequence dataSOX9 protein expressionTruncation mutantsAberrant splicingTranscription factor SOX9Protein stabilityOncoscan arrayTruncating mutationsCopy numberMutantsWT-TP53WT proteinMSK-IMPACTKRAS mutationsMolecular subtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply